Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;130(3):422-437.
doi: 10.1007/s11547-025-01961-9. Epub 2025 Feb 12.

Baseline 18F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters

Silvia Taralli  1 , Armando Orlandi  2 , Pia Clara Pafundi  3 , Valeria Tempesta  4 , Alba Di Leone  5 , Letizia Pontolillo  2 , Lorenzo Scardina  5 , Margherita Lorusso  4 , Ida Paris  6 , Maria Lucia Calcagni  4   7
Affiliations

Baseline 18F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters

Silvia Taralli et al. Radiol Med. 2025 Mar.

Abstract

Purpose: To investigate metabolic parameters from baseline 18F-FDG PET/CT as predictors of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and disease recurrence in locally advanced breast cancer (LABC) patients.

Materials and methods: From 142 LABC in 137 patients (bilateral-synchronous BC: 5/137), the following parameters from baseline (pre-treatment) 18F-FDG PET/CT were retrospectively analyzed, along with clinic-histological data: primary tumor activity (SUVmax, SUVmean, SUVpeak, tumor-to-liver ratio-TLR-, MTV, TLG); lymphoid organs activity (spleen and bone marrow SUVmax and SUVmean, spleen-to-liver ratio-SLR-, bone marrow-to-liver ratio-BLR); and PET-positive lymph-nodes' number. Predictors of pCR and recurrence-free survival (RFS) were assessed by univariable logistic regression and Cox regression (significant or suggestive association: p < 0.05; p < 0.10).

Results: 74/142 tumors were "Luminal A/B HER2-", 44/142 "Luminal B HER2+/HER2+", 24/142 TNBC; pCR after NAC occurred in 26/142 tumors (18.3%) and disease recurrence at follow-up (45 ± 18.1 months) in 25/127 assessable patients (19.7%). Significant or suggestive predictors of NAC response, in Luminal A/B HER2-: lower spleen SUVmax and patients' age (OR 0.06; 0.93) for pCR; lower TLRmax, TLRmean and BLRmax (OR 1.33; 1.22; and 26.42) for residual disease. Significant negative RFS predictors: higher SUVmax, SUVmean, SUVpeak (HR 1.10; 1.15; 1.11), TLRmax and TLRmean (HR 1.02; 1.00), MTV and TLG (HR 1.32; 1.26) in Luminal A/B HER2-; higher spleen SUVmax, PET-positive nodes' number and patients' age (HR 6.24; 1.20; 1.08) in Luminal B HER2+/HER2+.

Conclusion: Primary tumor and lymphoid organs parameters at baseline 18F-FDG PET/CT resulted as predictors of NAC response and prognosis in LABC patients, respectively, reflecting the BC cells' proliferative activity and metabolic burden, and the role of tumor-induced immune-system activation on tumors' behavior and treatment responsiveness. In LABC candidates to NAC, baseline PET information could improve treatment planning and prognostic stratification.

Keywords: 18F-fluoro-deoxy-glucose; Breast cancer; Neoadjuvant chemotherapy; PET/CT; Pathological response; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors have declare that they have no conflict of interest. Ethics approval: The study was performed in accordance with the principles of the 1964 Helsinki declaration and approved by the local ethics committee (ID 6754). Informed consent: Informed consent was obtained from all individual participants included in the study.

References

    1. Gennari A, André F, Barrios CH et al (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475–1495 - DOI - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1.2024. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf .
    1. Teichgraeber DC, Guirguis MS, Whitman GJ (2021) Breast cancer staging: updates in the AJCC cancer staging manual, 8th ed., and current challenges for radiologists, from the AJR special series on cancer staging. AJR 217:278–290 - DOI - PubMed
    1. Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172 - DOI - PubMed
    1. Mieog JS, van der Hage JA, van de Velde CJ (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94(10):1189–1200 - DOI - PubMed

Substances

LinkOut - more resources